BOCOM INTL (03329.HK): Xiao Ting has been appointed as the Director.

Gelonghui reported on January 20 that BOCOM INTL (03329.HK) announced that Wang Yongqing has resigned as a non-executive director due to a job transfer, effective from January 20, 2025. Xiao Ting has been appointed as a non-executive director, effective from January 20, 2025. Tan Yueheng will no longer serve as the Chairman of the Board of Directors due to work requirements, effective from January 20, 2025. After stepping down as Chairman, Tan Yueheng will remain an executive director of the company. Xiao Ting has been appointed as Chairman, effective from January 20, 2025.

Gelonghui FinanceJan 20 03:45 ET

Express News | BOCOM International - Tan Yueheng Ceased to Be Chairman

ReutersJan 20 03:40 ET

Bocom International Unit Acquires Bonds by Sumitomo Mitsui Banking

MT NewswiresJan 16 01:47 ET

BOCOM INTL: Maintaining Great Wall Motor's "Buy" rating with a Target Price of 17.36 Hong Kong dollars.

BOCOM INTL released a research report stating that it maintains a "Buy" rating on Great Wall Motor (02333), with a Target Price of HK$17.36. Great Wall Motor's progress towards high-end and Asia Vets has been relatively smooth, dominating the Chinese SUV market with rugged off-road models (such as Tank 300 and Tank 500), and successfully expanding into the high-end SUV market. In terms of Global layout, Great Wall Motor has established production bases and R&D centers in Russia, Thailand, India, and Brazil, achieving localized production and sales. The firm believes that the increase in the proportion of high-end models and the export layout will likely support profit growth. BOCOM INTL mainly

Sina Hong Kong stocksJan 15 21:42 ET

BOCOM INTL (03329) subsidiary acquires the second batch of SUMI notes.

BOCOM INTL (03329) announced that on January 14, 2025, the company's direct wholly-owned subsidiary Pr...

Zhitong FinanceJan 15 06:46 ET

BOCOM INTL: SIMCERE PHARMA's self-developed blood tumor/autoimmune triple antibody has successfully authorized the AbbVie TCE platform, marking the first endorsement by an MNC.

BOCOM INTL released a research report stating that SIMCERE PHARMA (02096) has reached a licensing option agreement with AbbVie (ABBV.US/not rated) regarding SIM0500 (BCMA x GPRC5D x CD3 tri-specific antibody). According to the agreement, AbbVie will have the licensing option rights for SIM0500 and will pay SIMCERE an upfront payment, as well as a maximum of $1.055 billion in option payments and milestone payments. After the product is approved for market, SIMCERE will also receive additional tiered sales commissions for regions outside Greater China, while AbbVie will have the right to receive tiered sales commissions for Greater China.

Sina Hong Kong StockJan 14 21:41 ET